Brimonidine intervention for Ectropion

Phase-Based Progress Estimates
University of Louisville, Louisville, KY
Ectropion+4 More
Brimonidine Topical - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to observe and report the effects of topical ophthalmic brimonidine in oculofacial plastic surgery.

Eligible Conditions

  • Ectropion
  • Entropion
  • Dermatochalasis of Eyelid
  • Blepharoptosis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: At the time of surgery.

At the time of surgery.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Control Arm
1 of 2
Brimonidine intervention
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Brimonidine intervention · No Placebo Group · Phase 4

Brimonidine intervention
Experimental Group · 1 Intervention: Brimonidine Topical · Intervention Types: Drug
Control ArmNoIntervention Group · 1 Intervention: Control Arm · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at the time of surgery.

Trial Background

Prof. Christopher Compton, Associate Professor
Principal Investigator
University of Louisville
Closest Location: University of Louisville · Louisville, KY
Photo of ky university of louisville  1Photo of ky university of louisville  2Photo of louisville  3
2017First Recorded Clinical Trial
1 TrialsResearching Ectropion
299 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.